reason report
anoth rais strength across entir busi
pt
bottom line veeva report strong result nearli
metric beat svb leerink/consensu estim guidanc
impress guid increas manag
highlight grow custom base continu success
exist custom cite growth across board veeva vault
continu strong momentum driver contribut nearli
revenu veeva continu grow market
share commerci cloud gain traction engag meet
larg custom expand presenc small
medium-s busi continu expans outsid
life scienc provid long-term term growth potenti
like veeva continu drive growth metric
expand product base custom base share
custom wallet believ compani strong product
pipelin continu drive growth futur
reiter op rate increas price target
strong result beat top bottom revenu
y/i beat svb leerink/consensu
subscript revenu y/i well ahead svb
leerink/consensu driven part quarterli
record vault custom add adj oper incom
y/i beat svb leerink/consensu
oper incom beat ad adj ep primarili driven
strong subscript revenu improv gross margin adj ep
y/i beat svb leerink/consensu
driven strong perform across board encourag
veeva continu display strong growth revenu continu
mid- rang well way becom fifth
saa compani surpass revenu
guidanc ahead estim expect
revenu y/i midpoint ahead
prior svb leerink consensu adj oper
incom quarter expect rang
y/i midpoint also ahead prior svb leerink/consensu
final adj ep guidanc
y/i midpoint compar prior svb leerink/consensu
view guidanc good indic sustain
growth compani continu expect increas
momentum new exist product
net debt total capit
price-to-earnings lt ep growth
outstand includ treatment stock option use
treasuri method
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million ep non-gaap
pleas refer page import disclosur price chart analyst certif
guidanc continu momentum revenu guidanc
exce prior svb leerink/consensu
adj oper incom expect rang
also ahead prior svb leerink/consensu
adj ep guidanc ahead prior
svb leerink/consensu impress veeva
pace exceed initi run rate well ahead
initi plan furthermor compani alreadi surpass adj
oper margin goal continu beat svb leerink
street expect beat revenu ep time
adj oper incom time past year remain
encourag compani growth prospect move forward
continu win new custom among increas competit
veeva vault nearli total subscript revenu
call manag highlight variou vault achiev quarter
includ top custom win cdm potenti
becom figur per year deal manag describ cdm
clinic data manag system applic mission critic
allow custom collect data research site faster
accur way allow quicker trial accur data
flow expect multi-year roll-out custom
maximum capac encourag see big win
top one biggest singl applic clinic side
busi manag also highlight vault achiev
includ multi-product deal top eu custom vault
regulatori four earli adopt vault safeti encourag
veeva continu drive vault platform forward
ai advanc progress nice manag referenc
hundr custom annual commerci summit
interest andi signific halo potenti
compani expand use veeva also expand ai
presenc area busi commerci
approv note help drive complianc sale rep free
text comment nitro andi expect drive revenu
futur nitro revenu driven size organ andi
per user per month basi
busi outsid life scienc continu show earli
qualiti one help custom manag product claim life cycl
convers custom regard need
manag suggest aggress market
still lot learn mani move part differ
type compani like veeva aggress new
market pursu opportun drive futur growth busi
new custom much busi shift in-sel
veeva remain debt free cash short-term
invest debt believ veeva well posit grow
organ acquisit view balanc sheet
healthi allow compani pursu strateg
opportun futur opportun aris
tweak estim updat estim reflect
strong quarter guidanc remain encourag compani
potenti grow industri believ continu success
justifi valuat remain op share
increas pt
inc lead industri cloud platform life scienc
consid biopharma market svb leerink veeva one profit
cloud saa vendor thrive life scienc industri veeva offer variou cloud base
softwar solut compani look benefit central data collect
manag analysi veeva applic util like salesforc platform
salesforc com amazon web servic span entir life cycl drug develop
initi clinic trial market sale allow streamlin process maxim
valu custom number veeva product use industri leader includ
novarti merck compani addit veeva
product suit provid emerg life scienc compani opportun compet
industri leader access capabl abil evolv chang
technolog custom market see life scienc industri expand cloud
oper next year compani realiz valu add data central
potenti time save bring drug market one veeva recent launch
platform qualityon provid avenu revenu diversif begin expand
busi target industri outsid life scienc includ chemic compani
consum packag good food beverag oil ga highli regul servic
platform provid document control qualiti manag recent roll
custom encourag inc industri potenti
whole move forward believ veeva posit market leader
increasingli competit grow environ result rate share
veeva volatil stock fairli high risk past week stock trade
high low view stock suitabl investor will
bear signific risk high-growth somewhat volatil market rel stock
tradit healthcar technolog univers trade high price-to-earnings ev/ebitda
ev/sal multipl howev rel non-healthcar enterpris softwar saa
cloud solut trade much reason level also believ dcf
basi reason price current trade ev/ebitda
estim premium legaci hcit group averag howev estim
overal enterpris softwar saa healthcar cloud ev/ebitda averag
believ deserv trade higher multipl peer given high
y/i top-lin growth rate opportun fast grow market also
gener adjust oper incom margin well enterpris
group averag veev manag team consist beaten investor expect
firm work expand new market sector within outsid life
scienc next month expect share trade
ev/ebitda ev/ebitda figur may sound high
compani like trade multipl higher
tradit legaci hcit vendor busi much robust growth profil
veeva rather high price multipl compar similar compani rel high
multipl still pose threat valuat compani continu grow around
annual futur earn offer opportun bring multipl back sustain
level time stock continu grow still see risk rel high price
multipl small swing may result oversel saw octob
life scienc compani begin switch infrastructur cloud veeva may
experi increas competit legaci competitor industri focus
sap well industri focus competitor medidata iqvia
competit custom yet make full switch cloud base
bargain power option legaci firm abl provid
capit research develop toward industri well determin
benefici long term
expand new industri
veeva dedic time resourc toward provid cloud base client outsid
life scienc industri qualityon product diversif plan may challeng
cloud base provid previous competitor veeva new
competitor may industri specif platform veeva would compet
diversifi away life scienc industri may indic current custom
focus grow product line industri long term
histor larg portion veeva revenu come small number custom
fiscal year veeva top ten custom account
total revenu one custom account revenu although
expand custom base improv revenu diversif within life scienc
sector still custom would pose threat revenu decid switch
competitor null contract anoth reason
veeva multipl on-going litig matter claim file
first iqvia formerli quintil im incorpor im softwar servic ltd collect
iqvia file complaint januari alleg unauthor access iqvia proprietari
data improv veeva softwar data product way veeva design
softwar steal trade secret iqvia accus continu alleg unauthor access
proprietari inform gain unfair advantag market veeva product
multipl claim veeva made fals
march veeva file counterclaim alleg iqvia abus monopoli power
domin provid data product life scienc compani exclud veeva product
respect network claim accus iqvia engag tactic prevent
custom switch veeva product increas difficulti cost switch platform
involv compani still wait court rule rule favor iqvia could result
damag veeva brand oper stock price
also januari medidata file complaint veeva five individu employe
previous work medidata complaint alleg veeva induc individu
breach employ agreement includ non-compet confidenti claus
misappropri medidata confidenti trade secret inform complaint
amend twice includ voluntari dismiss individu without prejudic veeva
motion compel arbitr deni argu appel court august
veeva current await rule court appeal second circuit rule
favor medidata may result damag veeva brand oper stock price
veeva experi secur breach regard sensit patient inform one
platform risk neg press caus damag brand reput
veeva sale cycl span period year commerci cloud year
veeva vault contract size variabl well depend number user
custom sign typic user base begin small grow length
contract howev renew isnt guarante also possibl upon renew custom
may expand suit result lower expect retent revenu
mani veeva vault custom small earli stage pre-commerci compani expect
compani may reach commerci howev present
signific earn potenti natur clinic trial like drug
obtain fda approv small compani drug make process
veeva risk lose member custom base
depend third parti
veeva oper depend amazon web servic product
includ veeva veeva vault respect well veeva commerci cloud
applic provid infrastructur data center part veeva
multichannel applic also includ system administr configur report
function agreement expir septemb renew
mutual agreement five-year period minimum order commit million must
met term agreement total million septemb full
million contract expir septemb veeva equal exceed
amount true payment requir would neg impact earn
potenti stock price upon expir agreement via one parti elect
renew termin via breach five-year wind
period platform could still offer exist custom limit number
new custom veeva breach contract oper would
sever risk host platform veeva migrat signific amount comput
infrastructur need amazon web servic risk disrupt outag downtim
cost increas issu
inform regard regul
custom depend veeva product produc relev accur inform
time veeva must ensur full complianc strict adapt regul failur
compli regul includ audit trail track electron signatur captur data
encrypt secur access control industri specif regul may result lawsuit
neg press hinder compani abil perform advers effect
varianc million
revenu
total revenu
research develop
revenu
sale market
revenu
gener administr
revenu
revenu
beat driven subscript
estim beat ep
beat benefit ep
bp ahead estim
bp ahead estim
bp behind estim declin revenu y/i
in-lin declin revenu y/i
bp ahead estim
bp ahead estim revenu
total opex slightli estim headwind
bp ahead model
beat ep lead gross profit
bp ahead lt estim strong bp y/i
ahead estim ep
provis incom tax
line estim
beat strong revenu lower cost revenu
incom statement fye januari non-gaap
revenu
profession servic
revenu
revenu
subscript servic
revenu
profession servic
revenu
total revenu
revenu
prof servic gross profit
research develop
revenu
sale market
revenu
gener administr
revenu
revenu
provis incom tax
